Health Care & Hospital Law
Oct. 27, 2011
Pay-for-delay agreement decline in 2011
Patent litigation settlement agreements between pharmaceutical companies and generic drugmakers dropped from 31 in fiscal year 2010 to 28 in 2011.
By Mandy Jackson
Daily Journal Staff Writer
The Federal Trade Commission reported on Tuesday that the number of so-called "pay-for-delay" patent litigation settlement agreements between pharmaceutical companies and generic drugmakers dropped from 31 in fiscal year 2010 to 28 in 2011.
In the deals, pharmaceutical firms and generic competitors agree to delay the launch of generic drugs, but allow the low-cost pills on the market before the brand-name drug's patents exp...
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In